Loading...
Market
Which treatment will have the largest market share for Alzheimer's in Japan by end of 2025?
2
Resolution / Starting Odds
Kisunla™ > Leqembi • 25%
Leqembi > Kisunla™ • 25%
Kisunla™ and Leqembi have equal market share • 25%
Other treatments lead • 25%
Market analysis reports from reputable sources such as IQVIA or Frost & Sullivan
Story
Eli Lilly's Kisunla™ for Early Symptomatic Alzheimer's Approved in Japan
Sep 24, 2024, 11:03 AM
Eli Lilly's Alzheimer's drug, Kisunla™ (donanemab-azbt), has received approval from Japan's health ministry for the treatment of early symptomatic Alzheimer's disease. This approval provides patients with another treatment option following the approval of Eisai and Biogen's Leqembi in September last year. The approval marks a significant breakthrough in the fight against dementia, with over 5 million cases projected in Japan by 2030. Eli Lilly's stock rose +0.2% pre-market following the news.
View original story
Similar markets
DDL-920 • 25%
Aduhelm • 25%
Leqembi • 25%
Other • 25%
Kisunla™ • 33%
Leqembi • 33%
Other/new drugs • 33%
Donanemab leads • 25%
Leqembi leads • 25%
Both have equal share • 25%
Other treatments lead • 25%
Eli Lilly • 25%
Eisai and Biogen • 25%
Other companies • 25%
No dominant company • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Leader • 25%
Top 3 • 25%
Top 5 • 25%
Not in Top 5 • 25%
BridgeBio Pharma • 25%
Pfizer • 25%
Other • 25%
Tie • 25%
Apitegromab • 25%
Evrysdi • 25%
Spinraza • 25%
Other • 25%
Kisunla > 50% • 25%
Kisunla 30-50% • 25%
Kisunla 10-30% • 25%
Kisunla < 10% • 25%
Below 10% • 33%
10-20% • 33%
Above 20% • 33%
PrecivityAD2™ dominates (>50%) • 25%
Sunbird Bio dominates (>50%) • 25%
Both share equally (~50% each) • 25%
Other diagnostic tests dominate • 25%